FMP
Harmony Biosciences Holdings, Inc.
HRMY
NASDAQ
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
34.32 USD
1.6 (4.66%)
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
159.74M
305.44M
437.86M
582.02M
714.73M
1.05B
1.56B
2.3B
3.39B
5B
Operating Cash Flow
-2.98M
98.56M
144.47M
219.39M
219.82M
278.12M
410.43M
605.68M
893.81M
1.32B
Cap Ex
-2M
-100.3M
-40.17M
-312k
-1.15M
-91.72M
-135.35M
-199.75M
-294.77M
-435M
Free Cash Flow
-4.99M
-1.74M
104.29M
219.07M
218.67M
186.4M
275.07M
405.93M
599.04M
884.02M
Wacc
8.69
8.69
8.69
8.69
8.69
Pv Lfcf
171.5M
232.85M
316.15M
429.25M
582.81M
Sum Pv Lfcf
1.73B
